ORM for Pharma Brand Managers India 2026 Framework

TL;DR: ORM for Indian pharma brand managers in 2026

• Indian pharma ORM in 2026 is a four-surface problem: Google Search plus Business Profile, Meta platforms (Instagram and Facebook), YouTube and Shorts, and closed WhatsApp groups of doctors, chemists and medical representatives. Miss any one surface and your brand narrative slips.
• The DPDP Act 2023 has made "screenshot and share" outreach risky. Every ORM workflow now needs a lawful basis, a retention window and a takedown protocol before you touch a single review.
• Doctor and chemist sentiment moves faster than patient sentiment. A single MR WhatsApp forward can shift 40 to 60 prescribers in a city within 72 hours, which is faster than any paid campaign can respond.
• At ICG we run pharma ORM under the 70-30 fixed-variable model. Foundation starts at Rs 49,999 per month, Growth at Rs 74,999 and Scale at Rs 99,999, with variables tied to sentiment shift, share of voice and complaint-resolution SLA.

Table of contents

• Why does ORM matter more for Indian pharma brand managers in 2026?
• What does the DPDP Act 2023 change for pharma ORM in India?
• Which surfaces should an Indian pharma brand actually monitor?
• Which reputation signals should brand managers track every week?
• How should a pharma brand handle a negative review from a doctor or chemist?
• What role do YouTube and Instagram play in pharma brand reputation?
• How do Indian pharma brands show up correctly on ChatGPT, Gemini and Perplexity?
• How does ICG structure ORM for pharma brands under the 70-30 model?
• FAQ

Why does ORM matter more for Indian pharma brand managers in 2026?

ORM matters more in 2026 because the Indian pharma buyer is no longer just a doctor in a chamber. It is a doctor scrolling Instagram between OPD, a chemist checking Google reviews before stocking a new molecule, and a patient asking a WhatsApp group whether your brand is a fair substitute. Your brand equity now lives on surfaces you do not control.

India's pharma market is projected to cross USD 130 billion by 2030, and roughly 68 to 72 percent of urban prescription decisions are now influenced by a digital touchpoint at some point in the funnel, either by the doctor herself or by the patient asking back. The MR is still central, but the MR is competing with a Reel that got 40,000 views last night.

For brand managers in Mumbai, Hyderabad, Ahmedabad, Bengaluru and Chandigarh, the practical shift is this: reputation is not a PR quarterly report anymore. It is a daily operating rhythm, and it needs to sit inside the brand plan next to price, place and promotion.

What does the DPDP Act 2023 change for pharma ORM in India?

The Digital Personal Data Protection Act 2023 changes three things for pharma ORM in India. First, any personal data you capture from a review, complaint or DM now needs a lawful basis and a stated purpose. Second, retention has to be time-bound. Third, patients and doctors can ask you to erase what you hold about them, and you have to comply within a reasonable window.

What this means on the ground for a pharma brand manager:

• Your ORM tool cannot silently scrape and store patient names attached to a complaint about a molecule. If your vendor is doing this, the liability sits with you as the data fiduciary.
• Doctor WhatsApp screenshots, which have been the informal currency of pharma ORM for a decade, are now legally sensitive. Sharing a screenshot of a doctor's private message without her consent is a defensible risk you should stop taking.
• Your customer-care and pharmacovigilance teams need a clear escalation flow. An adverse event mentioned inside a Google review is not just a reputation issue, it is a regulatory one, and the two clocks run in parallel.

The NMC Professional Conduct Regulations 2023 add another layer. Doctors endorsing pharma brands on Instagram or YouTube without proper disclosure can invite disciplinary action, which puts your influencer programme squarely in the ORM risk register.

Which surfaces should an Indian pharma brand actually monitor?

An Indian pharma brand in 2026 should monitor seven surfaces in a defined cadence. Not all seven need daily attention, but all seven need an owner. If nobody in your team owns a surface, that is where your next reputation crisis will start.

For a national brand in a competitive therapy area like cardiology, gastroenterology or dermatology, we typically see 4,000 to 12,000 brand mentions a month across these seven surfaces. Manual monitoring stops working past roughly 800 mentions a month, which is where structured tooling and a defined triage protocol have to take over.

Which reputation signals should brand managers track every week?

Brand managers should track five signals every week, and they should be reviewed in a 30-minute Monday standup with marketing, medical and the field force. If your Monday ORM review takes more than 30 minutes, your dashboard is too noisy and your triage rules are not tight enough.

• Share of voice by molecule and by city. A national number hides the reality. A brand can be at 34 percent SOV in Bengaluru and 6 percent in Kanpur in the same week.
• Sentiment score, split by audience. Doctor sentiment and patient sentiment move independently and often in opposite directions. Blending them into one number is one of the most common ORM mistakes we see.
• Complaint resolution SLA. How many hours between a complaint appearing on a public surface and your first substantive response. Under 6 hours on weekdays and under 12 hours on weekends is a reasonable 2026 benchmark for tier-1 Indian pharma brands.
• Review velocity on Google Business Profile. For pharma this is usually your corporate office listing plus depot listings. A sudden burst, positive or negative, almost always points to a coordinated event that needs investigating.
• Video velocity. New Reels and YouTube Shorts that mention your brand or your molecule, especially by doctors and pharmacists. This is the highest-leverage early-warning signal we track for pharma clients.

How should a pharma brand handle a negative review from a doctor or chemist?

The right first move on a negative review from a doctor or chemist is not to reply publicly. It is to identify the reviewer through the field force, understand the underlying reason offline, resolve it if possible, and then decide whether a public response is warranted. Public replies to angry reviewers almost always inflame the thread further.

A workable playbook we use for pharma clients:

• Hour 0 to 2: Log the review in your ORM tracker with mention, sentiment, therapy area, city and platform. Do not reply yet.
• Hour 2 to 24: Route to the RSM or ASM for the relevant territory. The field force identifies the reviewer where possible, and the medical or QA team is looped in if the review mentions an adverse event, side effect, or product quality issue.
• Hour 24 to 48: Offline resolution attempted. If the reviewer is a chemist with a genuine supply or margin complaint, distribution is looped in. If it is a doctor complaint about efficacy, medical takes over.
• Hour 48 to 72: If offline resolution is complete and the reviewer is willing, they update or remove the review themselves. If not, a calm, non-defensive public reply from the brand acknowledging the concern, without disclosing any personal detail, and directing them to a private channel is posted.

Never argue on a public thread. Never expose a patient identifier or a doctor's registration number in a reply. Never delete or bury negative reviews using paid tactics, because in the Indian pharma context a leaked screenshot of that behaviour is a bigger reputational hit than the original review would have been.

What role do YouTube and Instagram play in pharma brand reputation?

YouTube and Instagram now carry the loudest and most durable pharma reputation signals in India. A Reel from a Bengaluru dermatologist reviewing a new topical brand can reach 200,000 doctors and patients in 48 hours. A YouTube long-form from a Hyderabad cardiologist explaining a molecule ranks for years and quietly shapes prescribing behaviour long after the video is uploaded.

Three practical implications for pharma brand managers:

• You need a doctor-creator strategy, not just an influencer campaign. The doctors with the highest ORM impact are usually not the ones with the largest follower counts. They are mid-tier specialists in tier-1 and tier-2 cities who post consistently, have engaged comment sections and get quoted by other doctors.
• YouTube is your search engine, not just your video channel. When a patient in Pune types "is X molecule safe in pregnancy" into YouTube, the first three videos define your brand for that query for the next 18 to 24 months. Optimise for those queries, not for view count.
• Instagram Reels are your early warning system. A negative Reel typically peaks within 72 hours. If you catch it in the first 12, you can respond with a counter-Reel from a credible doctor voice and neutralise it before it becomes a WhatsApp forward.

ICG's YODA product is built specifically for this. It runs AI-native YouTube for healthcare brands, with a focus on ranking for doctor and patient queries in the Indian context rather than chasing vanity views. Meta Catalyst IQ and Prism Pulse handle the Meta and Instagram side, with Prism Spy providing competitor Meta Ads intelligence so brand managers know what rival molecules are running before their MRs get asked about it in a chamber.

How do Indian pharma brands show up correctly on ChatGPT, Gemini and Perplexity?

Indian pharma brands show up correctly on generative AI engines when their owned content, third-party medical content and structured data all agree on the same facts about the molecule, indication and brand. If any of those three sources disagree, the AI engine picks the loudest, which is rarely the most accurate.

A monthly AI-engine audit for a pharma brand should answer four questions:

• When a doctor asks ChatGPT or Gemini about your molecule, is your brand cited, and is it cited accurately?
• When a patient asks Perplexity about a symptom your molecule treats, does your brand appear in the answer, and does the citation link to a page you own?
• Are the AI engines pulling any outdated or incorrect claim about your brand, especially around dosage form, indication or availability in India?
• Are competitor molecules being cited in situations where your brand should be, and if yes, which content gap is causing that?

This is a new discipline. Most Indian pharma brands are two to three quarters behind on AI-engine hygiene, which means brand managers who fix this in 2026 will get a genuine window of advantage before the category catches up.

How does ICG structure ORM for pharma brands under the 70-30 model?

ICG structures pharma ORM under a 70-30 fixed-variable model. Seventy percent of the fee covers the always-on monitoring, triage, reporting and content operations. Thirty percent is variable and tied to outcomes the brand manager and CMO care about: sentiment shift, share of voice, complaint-resolution SLA and video ranking on YouTube for defined molecule queries.

Alongside the retainer, pharma brand managers usually plug in two ICG products: Nexus CRM at Rs 14,999 per month to manage doctor and KOL relationships in a DPDP-compliant way, and HealthPro 360 at Rs 14,999 per month where a hospital-facing overlay is needed for institutional brands. Angryturtle handles Google Business Profile operations for depot and corporate listings, which is where most silent damage happens on the search surface.

What the next 90 days should look like for a pharma brand manager reading this

If you are a brand manager in Mumbai, Hyderabad, Ahmedabad, Chandigarh or Bengaluru reading this on a Sunday evening, here is a defensible 90-day plan.

• Days 1 to 30: Audit all seven surfaces. Assign owners. Fix your Google Business Profile listings. Write a DPDP-aligned ORM SOP. Kill any "screenshot the doctor" workflow still running.
• Days 31 to 60: Set up your weekly signal dashboard. Onboard 5 to 8 doctor creators in your top 3 therapy areas. Run your first AI-engine audit. Start a Monday standup with medical, marketing and field.
• Days 61 to 90: Layer paid amplification through Meta and YouTube on the content that is already ranking organically. Publish your first quarterly ORM report to the CMO, with sentiment, SOV and SLA broken down by molecule and by city.

ORM done well is invisible to the doctor and boring to the finance team, which is exactly the point. It is the quietest lever on a pharma brand plan, and in 2026 it is one of the highest-leverage ones.